Automate Your Wheel Strategy on MDT
With Tiblio's Option Bot, you can configure your own wheel strategy including MDT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDT
- Rev/Share 27.1166
- Book/Share 38.1159
- PB 2.7184
- Debt/Equity 0.5981
- CurrentRatio 2.4153
- ROIC 0.0631
- MktCap 132340326309.0
- FreeCF/Share 4.0615
- PFCF 25.4207
- PE 27.7557
- Debt/Assets 0.3186
- DivYield 0.0274
- ROE 0.0983
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MDT | Citigroup | -- | Buy | -- | $117 | Feb. 3, 2026 |
| Resumed | MDT | Wells Fargo | -- | Overweight | -- | $114 | Jan. 30, 2026 |
| Upgrade | MDT | William Blair | Market Perform | Outperform | -- | -- | Jan. 6, 2026 |
| Upgrade | MDT | Goldman | Sell | Neutral | -- | $111 | Nov. 19, 2025 |
| Upgrade | MDT | Wolfe Research | Underperform | Peer Perform | -- | -- | June 30, 2025 |
| Initiation | MDT | Leerink Partners | -- | Outperform | -- | $110 | June 16, 2025 |
| Upgrade | MDT | Citigroup | Neutral | Buy | $92 | $107 | March 4, 2025 |
| Upgrade | MDT | RBC Capital Mkts | Sector Perform | Outperform | $98 | $105 | Oct. 10, 2024 |
| Reiterated | MDT | Oppenheimer | -- | Perform | $92 | $94 | Aug. 21, 2024 |
News
Medical device maker Medtronic to buy CathWorks in up to $585 million deal
Published: February 03, 2026 by: Reuters
Sentiment: Positive
Medtronic said on Tuesday it would buy privately held CathWorks in a deal valued at up to $585 million, as it looks to bolster its heart devices portfolio by adding a new diagnostic tool that could improve care standards.
Read More
Medtronic advances its innovation strategy with intent to acquire CathWorks
Published: February 03, 2026 by: PRNewsWire
Sentiment: Neutral
Deal demonstrates Medtronic's commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic's interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated Medtronic's intent to acquire follows a 2022 strategic partnership agreement with CathWorks GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 …
Read More
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
GALWAY, Ireland, Feb. 2, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin‑requiring type 2 diabetes. These milestones include Medicare access for the MiniMed™ 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system's use with ultra rapid‑acting insulins, and clearance of the MiniMed™ 780G system for use with the Instinct sensor for insulin-requiring type 2 diabetes.
Read More
Final Trades: Capital One, Medtronic, Transocean and Caterpillar
Published: January 23, 2026 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Medtronic: Don't Miss Out On This Dividend Aristocrat Now
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Medtronic is months away from upping its quarterly dividend per share for the 48th consecutive year. The medtech company's outsized demand for the Pulsed Field Ablation and Symplicity hypertension franchises are key growth drivers. Medtronic maintains an A S&P credit rating with a stable outlook.
Read More
ISRG vs. MDT: Which MedTech Stock Is a Better Bet Now?
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Neutral
Intuitive Surgical's pure-play robotics focus, rising da Vinci 5 utilization and 85% recurring revenues tilt the risk-reward versus diversified Medtronic.
Read More
3 Medical Device Companies in Focus for Monetizing Data and Analytics
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Neutral
Medtronic, IQVIA and GE HealthCare show how medical device leaders are turning analytics, AI and enterprise data platforms into recurring revenue engines.
Read More
3 MedTech Stocks Benefiting From Favorable Product Mix Shifts
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
Read More
MDT or ESLOY: Which Is the Better Value Stock Right Now?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Why Is Medtronic Stock Trading Higher After Analyst Upgrade
Published: January 06, 2026 by: Benzinga
Sentiment: Positive
On Tuesday, William Blair upgraded Medtronic Plc (NYSE: MDT), citing several new and ramping launches.
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
MDT vs. ESLOY: Which Stock Is the Better Value Option?
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Products stocks have likely encountered both Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
MiniMed Group Files For IPO In Medtronic Carve-Out
Published: December 22, 2025 by: Seeking Alpha
Sentiment: Positive
MiniMed Group, Inc., a Medtronic subsidiary, is targeting an IPO to fund growth and working capital amid diabetes device market expansion. MMED is well-positioned in automated insulin delivery, boasting an integrated product stack, strong recurring revenue, and international reach. Financials show rising revenue and gross profit, but operating leverage remains limited due to high R&D and pending clarity on intercompany debt repayment.
Read More
4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Four large-cap MedTech leaders, MDT, ISRG, CAH, EW, appear well-positioned to extend their winning streaks in 2026 on resilient procedure demand and innovation.
Read More
Why Is Medtronic (MDT) Down 2% Since Last Earnings Report?
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Read More
Build a Stronger 2026 Portfolio With These 5 Dividend Aristocrats
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ATO, MDT, PEP, CAT and SPGI stand out as dividend aristocrats for 2026, offering decades of hikes, solid yields and defensive income.
Read More
Medtronic (MDT) Upgraded to Buy: Here's Why
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic (MDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
MDT or ESLOY: Which Is the Better Value Stock Right Now?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
MDT Stock Set to Benefit From the FDA Clearance of Hugo RAS System
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic gains from the FDA clearance of its Hugo RAS system, expanding U.S. access to robotic-assisted urologic surgery.
Read More
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.
Read More
Robotics can 'democratize good healthcare' worldwide: Medtronic CEO
Published: November 27, 2025 by: Fox Business
Sentiment: Positive
Medtronic Chairman and CEO Geoffrey Martha discusses the company's latest robotic innovation and how robotics can impact healthcare on 'The Claman Countdown.' #fox #media #us #usa #new #news #foxbusiness #medtronic #robotics #technology #healthcare #medical #innovation #science #global #economy #business #ai #future #engineering #automation #medicine #healthtech
Read More
ISRG vs. MDT: A High-Tech Robotics Faceoff in the Race for Leadership
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Intuitive Surgical's robotics surge and Medtronic's broad innovation push set the stage for a high-tech showdown in next-gen minimally invasive care.
Read More
5 Must-Own Dividend Aristocrats That Can Weather a Coming Big Sell-Off
Published: November 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
The recent high-velocity sell-off may be a preview of what's to come this year or in 2026.
Read More
Medtronic plc (MDT) Q2 2026 Earnings Call Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Medtronic plc ( MDT ) Q2 2026 Earnings Call November 18, 2025 8:00 AM EST Company Participants Ryan Weispfenning - VP & Head of Investor Relations Geoffrey Martha - Chairman of the Board & CEO Thierry Pieton - Executive VP & CFO Laura Mauri - Senior VP and Chief Scientific & Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Travis Steed - BofA Securities, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Shagun Singh Chadha …
Read More
Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.
Read More
Medtronic (MDT) Q2 Earnings and Revenues Top Estimates
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic (MDT) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.26 per share a year ago.
Read More
Medtronic Lifts Outlook as Quarterly Profit, Sales Rise
Published: November 18, 2025 by: WSJ
Sentiment: Positive
Medtronic raised its fiscal-year outlook after logging higher profit and sales in its latest quarter, boosted by robust demand across end markets and healthy procedure volumes.
Read More
Medtronic Stock Rises After Earnings. What Caught Investors' Attention.
Published: November 18, 2025 by: Barrons
Sentiment: Positive
Medtronic exceeds fiscal second-quarter earnings and revenue expectations.
Read More
Medtronic beats second-quarter estimates on strength in heart devices segment
Published: November 18, 2025 by: Reuters
Sentiment: Positive
Medical device maker Medtronic topped Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its heart disease and diabetes devices.
Read More
Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland , Nov. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points above guidance midpoint GAAP diluted EPS of $1.07 increased 8%; non-GAAP diluted EPS of $1.36 increased 8%, above guidance Raising FY26 guidance: 5.5% organic revenue growth, …
Read More
About Medtronic plc (MDT)
- IPO Date 1973-05-02
- Website https://www.medtronic.com
- Industry Medical - Devices
- CEO Geoffrey Straub Martha
- Employees 95000